V

    Vyome Holdings, Inc. (HIND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.15
    -0.05 (-2.49%)

    Market Cap: $15.48M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(10/16)
    Avg Surprise
    -426.40%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.21 - $-0.21
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.21+0.0%
    60d ago$-0.21+0.0%
    30d ago$-0.20+4.8%
    7d ago$-0.20+4.8%
    Current$-0.21
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.23 - $-0.02
    2 analysts
    Revenue Consensus
    $150000
    Range$0 - $300000
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.21---
    Jun 26
    		$-0.10$-0.19+47.37%Beat+98.9%
    Mar 26
    		$-0.14$-0.18+20.06%Beat+94.2%
    Dec 25
    		$-0.21$-0.34+39.12%Beat+99.9%
    Sep 25
    		$-3.12$-0.11-2736.36%Miss+99.1%
    Jun 25
    		$-9.00N/AN/ABeat+98.3%
    Mar 25
    		$-2.47$-0.07-3428.57%Miss+100.0%
    Sep 24
    		$-310.70N/AN/ABeat+95.0%
    Jun 24
    		$-366.78N/AN/ABeat-978.1%
    Mar 24
    		$-542.24N/AN/ABeat-92590.6%
    Sep 23
    		$-5936.62N/AN/ABeat-1175468.2%
    Jun 23
    		$-6235.08N/AN/ABeat-1633403.6%
    Mar 23
    		$-34.02$-10.00-240.20%Miss-1866.5%
    Sep 22
    		$-0.58N/A+98.20%Beat-91.1%
    Jun 22
    		$-0.51$-0.51+0.98%Beat-245.4%
    Mar 22
    		$-0.38$-0.34-10.64%Miss+71.1%
    Dec 21
    		$-1.73$-0.17-888.57%Miss-239.2%
    Sep 21
    		$-0.31$-0.15-104.07%Miss+49.8%
    Jun 21
    		$-0.15$-0.22+33.55%Beat+91.0%
    Mar 21
    		$-1.32N/AN/ABeat+35.3%
    Dec 20
    		$-0.51N/A+83.00%Beat+100.0%
    Sep 20
    		$-0.61N/A+82.57%Beat+100.0%
    Jun 20
    		$-1.63N/A+89.13%Beat+100.0%
    Mar 20
    		$-2.04N/A+92.00%Beat+100.0%
    Dec 19
    		$-555633.92N/AN/ABeat+44.4%
    Sep 19
    		$-531940.09N/AN/ABeat+46.8%
    Jun 19
    		$-1000000.00N/AN/ABeat+0.0%
    Mar 19
    		$-1000000.00N/AN/ABeat+0.0%
    Dec 18
    		$-1000000.00N/AN/ABeat+0.0%
    Sep 18
    		$-1000000.00N/AN/ABeat+0.0%
    Jun 18
    		$-1000000.00N/AN/ABeat+0.0%
    Mar 18
    		$-1000000.00N/AN/ABeat+0.0%
    Dec 17
    		$-1000000.00N/AN/ABeat+0.0%
    Sep 17
    		$-1000000.00N/AN/ABeat+0.0%
    Jun 17
    		$-1000000.00N/AN/ABeat-
    Mar 17
    		$-1000000.00N/AN/ABeat-
    Dec 16
    		$-1000000.00N/AN/ABeat-
    Sep 16
    		$-1000000.00N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.60EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-3200.00%
    ROE-999.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-61.57x
    Current Ratio4.37xQuick Ratio4.37x
    Trading Statistics
    BetaN/AAvg Volume8.19K
    52-Week High$9.5652-Week Low$1.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.23
    SMA 20$2.21
    SMA 50$2.17
    SMA 200$2.74
    EMA 10$2.21
    EMA 20$2.20
    EMA 50$2.19
    EMA 200$6.23

    MACD

    Line: 0.01Signal: 0.02Hist: -0.01

    ADX

    ADX: 13.2+DI: 17.8-DI: 20.3

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$2.36

    Bollinger Bands

    Upper Band$2.32
    Lower Band$2.11
    %B Position949%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    45.4

    Momentum Oscillators

    Stoch %K28.6
    Stoch %D39.3
    Williams %R-87.5
    ROC (10d)-5.3%
    Momentum-0.12
    CCI (20d)-58.8
    MFI (14d)41.4

    Volatility Measures

    ATR (14d)$0.10(4.5%)
    StdDev (20d)0.05
    Hist Vol30.4%(Moderate)

    Volume Flow

    VWAP$2.17
    OBV912.6M
    AD Line534.0B
    CMF (20d)0.070

    Volume Metrics

    Avg Vol (20d)8.1K
    Vol Ratio0.9x
    VWMA (20d)$2.22

    Pivot Points

    R3$2.31
    R2$2.29
    R1$2.25
    Pivot Point$2.23
    S1$2.19
    S2$2.17
    S3$2.13

    Advanced Oscillators

    TSI4.02
    Ultimate Osc36.7
    KST40.69

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$26,955$31,591$-2,069,913$34,627$49,954$198,581$-3,736,582$84,526$1.97M$1.94M$1.98M$2.15M
    Cost of Revenue$15,297$14,946$-990,634$16,577$25,719$44,162$-1,595,467$47,441$831,000$779,000$140,000$867,000
    Gross Profit$11,658$16,645$-1,079,279$18,050$24,235$154,419$-2,141,115$37,085$1.13M$1.17M$1.84M$1.29M
    Operating Expenses$874,224$1.15M$-4,169,019$8.59M$348,424$353,417$-5,679,753$318,063$3.19M$3.38M$3.74M$5.17M
    R&D$506,723$666,405$-291,419$39,677$80,061$90,268$-664,424$66,815$399,000$484,000$739,000$542,000
    SG&A$364,891$477,575$-1,696,779$844,344$265,395$259,626$-3,126,249$246,821$1.91M$1.87M$-4,549,000$3.85M
    Operating Income$-862,566$-1,129,940$3.09M$-8,574,310$-324,189$-198,998$3.54M$-280,978$-2,054,000$-2,210,000$-1,896,000$-3,880,000
    Interest Income$0$0$0$0$0$0$0$0$4,000$9,000$17,000$5,000
    Interest Expense$3,325$2,845$145,037$25,604$56,139$54,954$589,262$45,742$-429,000$0$0$0
    Income Before Tax$-719,683$-985,521$-741,413$-8,595,300$-308,760$-293,974$2.86M$-548,410$-1,580,000$-2,179,000$-1,667,000$-3,531,000
    Income Tax Expense$0$0$0$0$0$0$0$0$15,000$14,000$31,000$3,000
    Net Income$-719,683$-985,521$-726,413$-8,595,300$-308,760$-293,974$2.89M$-547,772$-1,595,000$-2,193,000$-1,698,000$-3,534,000
    EBITDA$-713,748$-980,071$-615,688$-8,568,399$-249,653$-235,497$3.47M$-501,185$-2,007,000$-2,182,000$-1,669,000$-3,486,000
    EBIT$-716,358$-982,676$-618,376$-8,569,696$-252,621$-239,020$3.46M$-502,668$-2,013,000$-2,188,000$-1,676,000$-3,536,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HIND

    News

    ReShape Lifesciences Inc (RSLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for ReShape Lifesciences Inc (RSLS), noting a "Buy" analyst rating based on one analyst. It highlights a target price of $15.000, suggesting a potential upside of 161.78%. The information is presented by TradingKey, which emphasizes that analyst ratings are for informational purposes only and not investment advice.

    TradingKey•6/18/26•
    Neutral

    ReShape Lifesciences Inc (RSLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of ReShape Lifesciences Inc (RSLS), detailing its support, resistance, indicators, and moving averages. While specific support and resistance data are not disclosed, it presents a summary of various technical indicators like MACD, RSI, and KDJ, alongside moving average data from MA5 to MA200. The analysis concludes with a general "Buy" signal based on the combined technical indicators and moving averages.

    TradingKey•6/18/26•
    Neutral

    ReShape Lifesciences Inc (RSLS) Institutional Confidence

    This article from TradingKey focuses on the institutional confidence in ReShape Lifesciences Inc (RSLS). It provides a snapshot of the stock's current trading status, market capitalization, and lists key institutional shareholders along with their holdings. The report highlights that institutional shareholding currently has a score of 0, indicating no recent change.

    TradingKey•6/18/26•
    Neutral

    ReShape Lifesciences Inc (RSLS) Valuation: PE, PB & Fair Value Analysis

    This article provides a brief overview of ReShape Lifesciences Inc (RSLS) focusing on its stock valuation. It lists the current stock price, market cap, and indicates that relevant data for P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The page appears to be a stub or an incomplete analysis from TradingKey.

    TradingKey•6/18/26•
    Neutral

    ReShape Lifesciences Inc (RSLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

    This article provides a revenue breakdown for ReShape Lifesciences Inc (RSLS), showing geographical distribution. The data, updated as of July 6, highlights that the United States accounts for the largest portion of revenue at 83.65%, followed by Europe and Australia. The report indicates that business segment and profit contribution data have not yet been disclosed by the company.

    TradingKey•6/17/26•
    Neutral

    Frequently Asked Questions About HIND

    Does HIND pay dividends?
    Vyome Holdings, Inc. (HIND) does not currently pay a regular dividend.
    What is HIND's market cap?
    Vyome Holdings, Inc. (HIND) has a market capitalization of $15.48M with a current stock price of $2.15.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In